Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Both should have significant catalysts by the end of the decade.
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
NEW YORK, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- LB Pharmaceuticals Inc ( "LB Pharmaceuticals" or the "Company" ) ( Nasdaq: LBRX ) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September ...
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani - LB Pharmaceuticals ( NASDAQ:LBRX )
NEW YORK, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- LB Pharmaceuticals Inc ( "LB Pharmaceuticals" or the "Company" ) ( NASDAQ: LBRX ) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September ...
Peering Into Exelixis's Recent Short Interest - Exelixis ( NASDAQ:EXEL )
Exelixis's EXEL short interest as a percent of float has risen 4.39% since its last report. According to exchange reported data, there are now 17.63 million shares sold short, which is 9.03% of all regular shares that are available for trading.
Here's Why Exelixis ( EXEL ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL - Exelixis ( NASDAQ:EXEL )
NEW YORK, Sept. 06, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ( "Exelixis" or the "Company" ) EXEL. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Do Options Traders Know Something About Exelixis Stock We Don't?
Investors need to pay close attention to EXEL stock based on the movements in the options market lately.
Why Is Alkermes ( ALKS ) Up 4.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Exelixis ( EXEL ) Up 3.8% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise ...
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
Will EXEL's Share Repurchase Program Boost Value for Investors?
Exelixis repurchases shares for $796M, aiming to boost EPS and shareholder value through 2025.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL - Exelixis ( NASDAQ:EXEL )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ( "Exelixis" or the "Company" ) EXEL. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.
Is First Trust Health Care AlphaDEX ETF ( FXH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL - Exelixis ( NASDAQ:EXEL )
NEW YORK, Aug. 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ( "Exelixis" or the "Company" ) EXEL. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
Exelixis EXEL Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Monday, July 28, 2025 at 9:00 p.m. ETPresident & CEO - Michael M. MorrisseyContinue reading ...
Don't Overlook Exelixis ( EXEL ) International Revenue Trends While Assessing the Stock
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week ( July 28-August 1 ) : Are The Others In Your Portfolio? - ATI ( NYSE:ATI ) , Baxter Intl ( NYSE:BAX )
Novo Nordisk plunged 31% after slashing its 2025 sales outlook. UPS, Moderna, and Coinbase dropped on weak Q2 results and guidance. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday. These ten large-cap stocks were the worst performers ...
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
Is Exelixis ( EXEL ) a Solid Growth Stock? 3 Reasons to Think "Yes"
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
Investors looking for a momentum stock that could be in store for higher highs may want to consider Celestica (CLS), while those looking for a buy-the-dip target have an intriguing option with Exelixis (EXEL).
Exelixis Stuns Analyst With Q2 Miss, Trial Delays, Phase 3 Halt - Exelixis ( NASDAQ:EXEL )
Q2 sales reaches $568.3 million, missing estimates by about $3 million; EPS beat consensus at 75 cents vs. 56 cents. Exelixis halts STELLAR-305 phase 3 plans and delays STELLAR-304 readout to first half of 2026. Missed the rally? Learn exactly where the next leaders are emerging here. Exelixis ...
All You Need to Know About Exelixis ( EXEL ) Rating Upgrade to Strong Buy
Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Fulcrum Therapeutics ( NASDAQ:FULC ) , Exelixis ( NASDAQ:EXEL )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday. Shares of Whirlpool Corporation WHR fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 earnings guidance.
Exelixis Q2 Revenue Falls 11 Percent
Exelixis ( NASDAQ:EXEL ) , an oncology-focused biotech, reported results for Q2 2025 on July 28, 2025. For the period, the company delivered non-GAAP earnings per share ( EPS ) of $0.75 in Q2 FY2025, beating analyst consensus of $0.66.
Exelixis ( EXEL ) Beats Q2 Earnings Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +15.38% and -1.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Exelixis ( EXEL ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® ( cabozantinib ) for adult patients with unresectable or metastatic, well differentiated pancreatic ( pNET ) and extra-pancreatic ( epNET ) neuroendocrine tumors who have progressed following ...
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
Here's Why Exelixis ( EXEL ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What Analyst Projections for Key Metrics Reveal About Exelixis ( EXEL ) Q2 Earnings
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Alkermes ( ALKS ) Expected to Beat Earnings Estimates: Should You Buy?
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Peering Into Exelixis's Recent Short Interest - Exelixis ( NASDAQ:EXEL )
Exelixis's EXEL short percent of float has fallen 4.97% since its last report. The company recently reported that it has 19.38 million shares sold short, which is 9.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.44 days to cover ...
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Exelixis ( EXEL ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
A decade ago, shares of Exelixis ( NASDAQ: EXEL ) , a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45 apiece. In other words, Exelixis has crushed the market since 2015.Some might think there is little ...
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Will Exelixis ( EXEL ) Beat Estimates Again in Its Next Earnings Report?
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.
Tempus AI Raises 2025 Financial Outlook: What's Backing It?
TEM lifts its 2025 revenue and EBITDA outlook on strong Q1 results, key partnerships and testing expansion.
Exelixis ( EXEL ) is an Incredible Growth Stock: 3 Reasons Why
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Exelixis ( EXEL ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
